David Loew on acquisition of Epizyme
Epizyme welcome to Ipsen
Loading...
  • Media  arrow_down
    < Back
    • Press Releases
    • Media Statements
    • Media Library

    • Our 2023 Integrated Annual Report is live!

       Featured Image
  • Investorsarrow_down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports and Accounts
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Shareholder Information
    • Share-Price Data
    • Regulated Information
    • Key Contacts
  • Partnering
  • Careersarrow_down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Loading...
  • English  EN     Français  FR     EN  arrow_down
    • EnglishEN
    • FrançaisFR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
  • Home
  • Companyarrow_down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow_down
      < Back
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
    • Lay Summaries
  • Sustainabilityarrow_down
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patientsarrow_down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Stories
  3. General story

Epizyme welcome to Ipsen

Back

Post navigation

Previous
Next

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Epizyme welcome to Ipsen

- 12 August 2022 - 1 mins read
Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Post navigation

Previous
Next

Share this on social media

  • Share on LinkedIn
  • Share on Twitter
  • Share on Facebook

Related stories

Financial results for the first nine months of 2024
17 October 2024 0 mins read

Financial results for the first nine months of 2024
Financial results for the first half of 2024
22 July 2024 0 mins read

Financial results for the first half of 2024
Our 2023 Integrated Annual Report is live!
31 May 2024 1 mins read

Our 2023 Integrated Annual Report is live!
Q1 2024 sales update
19 April 2024 0 mins read

Q1 2024 sales update
Applications now open for the 2024 Golden Ticket competition
15 March 2024 2 mins read

Applications now open for the 2024 Golden Ticket competition
FY 2023 results announcement 
08 February 2024 0 mins read

FY 2023 results announcement 
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
20 November 2023 1 mins read

Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
Examining the European Pharma legislation: EFPIA publishes the Dolon Report
10 November 2023 1 mins read

Examining the European Pharma legislation: EFPIA publishes the Dolon Report
Capital Markets Day 2023
03 November 2023 0 mins read

Capital Markets Day 2023
2023 year to date and third-quarter sales results
23 October 2023 1 mins read

2023 year to date and third-quarter sales results

IPN price

€108.40

 €1.20 (1.12%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Sustainability
  • Patients
  • Stories
  • Annual Report
  • Contact us
Latest_Ipsen logo
LinkedIn Twitter Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2024

You are now leaving the Ipsen group website. To continue, please click on Continue?